NDAINTRA-ARTERIALSOLUTION
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ABLYSINOL (alcohol) by Gen Pharmaceuticals is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. Approved for gingivitis, hypertension, alcohol use disorder and 21 more indications. First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Worked on ABLYSINOL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.